The Molecular Mechanism for Differentiation Therapy of Malignant Glioma

Zhu, Wenbo; Gao, Yan

doi:10.5772/21215

Cited by 3 publications

(2 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Головним активним інгредієнтом чаю є поліфенол (епігаллокатехін-3-галлат). Поліфеноли чаю мають виражену протитуморозну активність [59]; основні механізми включають антиоксидантний ефект, імуномодуляторний ефект, інгібіцію експресії онкогенів, індукцію апоптозу та попередження пошкодження ДНК імуномодуляторний ефект, інгібіцію експресії онкогенів, індукцію апоптозу та попередження пошкодження ДНК [60]. Підвищена кількість вживання чаю була пов'язана зі зменшенням ризику РСМ взагалі, що підтверджено в сукупному аналізі 12 когортних досліджень (ВШ: 0,84; 95% ДІ: 0,75-0,95 відносно високого вживання).…”

Section: вплив професійних канцерогенівunclassified

Epidemiology of Bladder Cancer: Current Insight

Golovko

2024

ЗЧ

View full text Add to dashboard Cite

Bladder cancer (BC) is a 9th most common cancer in the world that make from 3% of global neoplasms. Bladder cancer is prevalent in the developed countries. Cancer of the bladder is four times more common in men than women. External risk factors and internal triggers contribute to the development of bladder cancer. Thus, comprehensive analysis of these risk factors is a earnest to timely prevention of indicated oncologic pathology. The objective: to do a current systematic review of epidemiology of bladder cancer and modern important risk factors, which appropriate to the given pathology. Evidence acquisition. We carried out a systemic review of epidemiology of bladder cancer embracing PubMed and Embase including March 2023. All studies reporting gender, smoking, E-cigarette use, opium consumption, occupational carcinogene expose, dietary factors, race, gene-environment interaction, socioeconomic status. Microbiome factors, urolithiasis, benign prostate hyperplasiapelvic radiotherapy were excluded. Evidence synthesis. A total of 516 papers, that studied epidemiology of bladder cancer, were involved. According to GLOBOCAN, there were 573 000 new bladder cancer cases and 213 000 deaths worldwide in 2020. Smoking and occupational exposures (aromatic amines and polycyclic aromatic hydrocarbons) are the most important risk factors. Moreover, the additional risk factors include some dietary agents, gene specificities, diesel exhaust emissions and etc. Conclusions. Smoking tobacco and specific occupational exposures are the most important risk factors. Prevention strategies, including smoke cessation, responsible workplace safety, diet, schistosomias prevention are useful for reduction of the incidence BC. But high-quality studies are required to confirm initial results that will support timely prevention of BC.

show abstract

Section: вплив професійних канцерогенівunclassified

Epidemiology of Bladder Cancer: Current Insight

Golovko

2024

ЗЧ

View full text Add to dashboard Cite

show abstract

“…The enzyme controls the differentiation of the cells of these brain tumors. Induction of the GSK-3 expression or expression of S9A mutant GSK-3 restores the sensitivity of differentiation-resistant cells and can be used as a therapeutic paradigm in malignant brain tumors [57]. A thorough review of GSK-3 role in brain tumors and their treatment is available [58].…”

Section: Role Of Gsk-3 Inhibition In Cancer: Recent Findingsmentioning

confidence: 99%

Glycogen Synthase Kinase 3 as an Anticancer Drug Target: Novel Experimental Findings and Trends in the Design of Inhibitors

Osolodkin

Palyulin

Зефиров

2012

CPD

View full text Add to dashboard Cite

Glycogen synthase kinase 3 (GSK-3) is a ubiquitous serine/threonine protein kinase participating in numerous pathways. Very important among them are cancer-related pathways, such as Wnt pathway and nuclear factor B pathway. The recent findings concerning possible applicability of GSK-3 inhibitors as anticancer agents are summarized in this review, and controversies in the data are highlighted. The most actual concepts of GSK-3 inhibitor design are also thoroughly discussed.

show abstract

Glycogen Synthase Kinase 3 as an Anticancer Drug Target: Novel Experimental Findings and Trends in the Design of Inhibitors

Osolodkin¹,

Palyulin²,

Зефиров³

2013

Current Pharmaceutical Design

View full text Add to dashboard Cite

Glycogen synthase kinase 3 (GSK-3) is a ubiquitous serine/threonine protein kinase participating in numerous pathways. Very important among them are cancer-related pathways, such as Wnt pathway and nuclear factor κB pathway. The recent findings concerning possible applicability of GSK-3 inhibitors as anticancer agents are summarized in this review, and controversies in the data are highlighted. The most actual concepts of GSK-3 inhibitor design are also thoroughly discussed.

show abstract

The Molecular Mechanism for Differentiation Therapy of Malignant Glioma

Cited by 3 publications

References 67 publications

Epidemiology of Bladder Cancer: Current Insight

Epidemiology of Bladder Cancer: Current Insight

Glycogen Synthase Kinase 3 as an Anticancer Drug Target: Novel Experimental Findings and Trends in the Design of Inhibitors

Glycogen Synthase Kinase 3 as an Anticancer Drug Target: Novel Experimental Findings and Trends in the Design of Inhibitors

Contact Info

Product

Resources

About